RU2017126701A - Способ детекции нуклеосом, содержащих нуклеотиды - Google Patents
Способ детекции нуклеосом, содержащих нуклеотиды Download PDFInfo
- Publication number
- RU2017126701A RU2017126701A RU2017126701A RU2017126701A RU2017126701A RU 2017126701 A RU2017126701 A RU 2017126701A RU 2017126701 A RU2017126701 A RU 2017126701A RU 2017126701 A RU2017126701 A RU 2017126701A RU 2017126701 A RU2017126701 A RU 2017126701A
- Authority
- RU
- Russia
- Prior art keywords
- base
- dna
- nucleosome
- sample
- biological fluid
- Prior art date
Links
- 108010047956 Nucleosomes Proteins 0.000 title claims 23
- 210000001623 nucleosome Anatomy 0.000 title claims 23
- 238000000034 method Methods 0.000 title claims 15
- 239000002773 nucleotide Substances 0.000 title 1
- 239000013060 biological fluid Substances 0.000 claims 14
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 12
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 12
- 239000011230 binding agent Substances 0.000 claims 8
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 6
- 229930010555 Inosine Natural products 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229960003786 inosine Drugs 0.000 claims 6
- 229940035893 uracil Drugs 0.000 claims 6
- 229940075420 xanthine Drugs 0.000 claims 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 3
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Claims (43)
1. Применение основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера в образце биологической жидкости в диагностике рака, причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания.
2. Применение по п.1, где внеклеточная нуклеосома представляет собой мононуклеосому или олигонуклеосому.
3. Применение по п.1, где основание ДНК, связанное с внеклеточной нуклеосомой, измеряют в образце крови.
4. Применение по п.1, где рак представляет собой рак мочевого пузыря, молочной железы, ободочной кишки, шейки матки, пищевода, почки, толстой кишки, легкого, полости рта, яичника, поджелудочной железы, предстательной железы, прямой кишки, кожи или желудка.
5. Применение по п.4, где рак представляет собой рак ободочной кишки, легкого, полости рта или поджелудочной железы.
6. Применение по п.1, где модифицированное основание выбрано из: 5-метилцитозина, 5-гидроксиметилцитозина или 7,8-дигидро-8-оксогуанина.
7. Способ детекции присутствия в образце биологической жидкости основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера, включающий следующие стадии:
(i) контакт образца биологической жидкости с первым связующим веществом, которое связывается с нуклеосомами;
(ii) контакт нуклеосом или образца биологической жидкости со вторым связующим веществом, которое связывается с основанием ДНК;
(iii) детекцию или количественное определение связывания указанного второго связующего вещества с основанием ДНК в образце биологической жидкости; и
(iv) использование присутствия или степени такого связывания в качестве меры присутствия в образце биологической жидкости основания ДНК, связанного с нуклеосомами,
причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания.
8. Способ по п.7, где модифицированное основание выбрано из: 5-метилцитозина, 5-гидроксиметилцитозина или 7,8-дигидро-8-оксогуанина.
9. Способ по п.7, где связующее вещество представляет собой антитело.
10. Способ по п.7, где образец биологической жидкости представляет собой кровь, сыворотку или плазму.
11. Способ детекции присутствия в образце биологической жидкости основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера, включающий следующие стадии:
(i) контакт образца биологической жидкости с первым связующим веществом, которое связывается с основанием ДНК;
(ii) контакт нуклеосом или образца биологической жидкости со вторым связующим веществом, которое связывается с нуклеосомами;
(iii) детекцию или количественное определение связывания указанного второго связующего вещества с нуклеосомами в образце биологической жидкости; и
(iv) использование присутствия или степени такого связывания в качестве меры присутствия в образце биологической жидкости основания ДНК, связанного с нуклеосомами,
причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания.
12. Способ по п.11, где модифицированное основание выбрано из: 5-метилцитозина, 5-гидроксиметилцитозина или 7,8-дигидро-8-оксогуанина.
13. Способ по п.11, где связующее вещество представляет собой антитело.
14. Способ по п.11, где образец представляет собой кровь, сыворотку или плазму.
15. Способ детекции состояния заболевания животного субъекта или человека, включающий следующие стадии:
(i) детекцию или измерение основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера в биологической жидкости субъекта; и
(ii) использование уровня связанного с нуклеосомами основания ДНК, измеренного для определения состояния заболевания субъекта,
причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания, и
причем заболевание представляет собой рак.
16. Способ по п.15, где основание ДНК, связанное с внеклеточной нуклеосомой, определяют или измеряют как один из параметров измерений.
17. Способ оценки животного субъекта или человека в отношении пригодности для терапевтического лечения, включающий следующие стадии:
(i) детекцию или измерение основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера в биологической жидкости субъекта; и
(ii) использование уровня связанного с нуклеосомами основания ДНК, определяемого в качестве параметра при выборе подходящего лечения для субъекта,
причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания, и
причем лечение проводят для лечения рака.
18. Способ по п.17, в котором основание ДНК, связанное с внеклеточной нуклеосомой, определяют или измеряют как один из параметров измерений.
19. Способ наблюдения лечения животного субъекта или человека, включающий следующие стадии:
(i) детекцию или измерение основания ДНК, связанного с внеклеточной нуклеосомой, в качестве биомаркера в биологической жидкости субъекта;
(ii) повторную детекцию или измерение основания ДНК, связанного с внеклеточной нуклеосомой, в биологической жидкости субъекта в один или несколько моментов времени; и
(iii) использование любых изменений уровня связанного с нуклеосомами основания ДНК, определяемого в качестве параметра любых изменений состояния субъекта,
причем основание ДНК выбрано из: урацила, инозина, ксантина, гипоксантина или модифицированного основания, и
причем лечение проводят для лечения рака.
20. Способ по п.19, где основание ДНК, связанное с внеклеточной нуклеосомой, определяют или измеряют как один из параметров измерений.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530295P | 2011-09-01 | 2011-09-01 | |
US61/530,295 | 2011-09-01 | ||
GBGB1115095.0A GB201115095D0 (en) | 2011-09-01 | 2011-09-01 | Method for detecting nucleosomes containing nucleotides |
GB1115095.0 | 2011-09-01 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014112350/15A Division RU2014112350A (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих нуклеотиды |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017126701A3 RU2017126701A3 (ru) | 2019-01-31 |
RU2017126701A true RU2017126701A (ru) | 2019-01-31 |
RU2687483C2 RU2687483C2 (ru) | 2019-05-14 |
Family
ID=44882046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014112350/15A RU2014112350A (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих нуклеотиды |
RU2017126701A RU2687483C2 (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих нуклеотиды |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014112350/15A RU2014112350A (ru) | 2011-09-01 | 2012-08-31 | Способ детекции нуклеосом, содержащих нуклеотиды |
Country Status (22)
Country | Link |
---|---|
US (2) | US10900064B2 (ru) |
EP (2) | EP2751568B1 (ru) |
JP (1) | JP6322845B2 (ru) |
KR (1) | KR102074528B1 (ru) |
CN (1) | CN104067124B (ru) |
AU (1) | AU2012300641B2 (ru) |
BR (1) | BR112014005087B1 (ru) |
CA (1) | CA2845993C (ru) |
DK (1) | DK2751568T3 (ru) |
ES (1) | ES2717659T3 (ru) |
GB (1) | GB201115095D0 (ru) |
HK (1) | HK1199760A1 (ru) |
HR (1) | HRP20190533T1 (ru) |
HU (1) | HUE043386T2 (ru) |
MX (1) | MX364410B (ru) |
PL (1) | PL2751568T3 (ru) |
PT (1) | PT2751568T (ru) |
RU (2) | RU2014112350A (ru) |
SG (2) | SG11201400270PA (ru) |
TR (1) | TR201904386T4 (ru) |
WO (1) | WO2013030577A1 (ru) |
ZA (1) | ZA201401295B (ru) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
EP2321642B1 (en) | 2008-08-04 | 2017-01-11 | Natera, Inc. | Methods for allele calling and ploidy calling |
US10113196B2 (en) | 2010-05-18 | 2018-10-30 | Natera, Inc. | Prenatal paternity testing using maternal blood, free floating fetal DNA and SNP genotyping |
ES2640776T3 (es) | 2009-09-30 | 2017-11-06 | Natera, Inc. | Métodos para denominar de forma no invasiva ploidía prenatal |
CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
CA2824387C (en) | 2011-02-09 | 2019-09-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
EP2775304A1 (en) * | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
WO2015048535A1 (en) * | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
CN113774132A (zh) | 2014-04-21 | 2021-12-10 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
WO2016049936A1 (en) * | 2014-09-30 | 2016-04-07 | Bgi Shenzhen Co., Limited | Biomarkers for rheumatoid arthritis and usage therof |
JP6721599B2 (ja) * | 2014-10-29 | 2020-07-15 | ベルジアン ボリション エスピーアールエル | 循環する腫瘍dnaの濃縮方法 |
JP6813503B2 (ja) * | 2015-02-10 | 2021-01-13 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | バイオマーカーとしての遊離ヒストンタンパク質 |
EP3294906B1 (en) | 2015-05-11 | 2024-07-10 | Natera, Inc. | Methods for determining ploidy |
US11111520B2 (en) | 2015-05-18 | 2021-09-07 | Karius, Inc. | Compositions and methods for enriching populations of nucleic acids |
GB201511512D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell-free nucleosomes as biomarkers |
GB201511542D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell free nucleosomes as biomarkers |
GB201518665D0 (en) | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
GB201518674D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for detecting nuleosomes containing histone modifications and variants |
GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
CN107858416B (zh) * | 2016-09-19 | 2021-05-28 | 深圳华大生命科学研究院 | 用于子宫内膜异位症检测的生物标志物组合及其应用 |
WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
CA3049139A1 (en) | 2017-02-21 | 2018-08-30 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
CN107164508A (zh) * | 2017-06-16 | 2017-09-15 | 上海易毕恩基因科技有限公司 | 用于检测肝癌的基因标志物及其用途 |
CN107385051A (zh) * | 2017-08-04 | 2017-11-24 | 上海易毕恩生物技术有限公司 | 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法 |
WO2019169263A1 (en) * | 2018-03-01 | 2019-09-06 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
JP2021520816A (ja) | 2018-04-14 | 2021-08-26 | ナテラ, インコーポレイテッド | 循環腫瘍dnaの個別化された検出を用いる癌検出およびモニタリングの方法 |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
BR112022003546A2 (pt) | 2019-08-27 | 2022-05-17 | Belgian Volition Srl | Método de isolar nucleossomos circulantes |
GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
WO2021110776A1 (en) | 2019-12-02 | 2021-06-10 | Belgian Volition Sprl | Use of cell free nucleosomes as biomarkers |
MX2022011614A (es) | 2020-03-20 | 2022-10-13 | Belgian Volition Srl | Metodo de triaje utilizando niveles de nucleosomas libres de celulas. |
TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
TW202242146A (zh) | 2021-01-13 | 2022-11-01 | 比利時商比利時意志有限公司 | 肺癌的檢測方法 |
GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
WO2023073179A1 (en) | 2021-10-29 | 2023-05-04 | Belgian Volition Srl | Homogeneous immunoassay method |
GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
WO2023170298A1 (en) | 2022-03-11 | 2023-09-14 | Belgian Volition Srl | Differential diagnosis method |
GB202205212D0 (en) | 2022-04-08 | 2022-05-25 | Belgian Volition Sprl | Method for transplant organ health assessment |
WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
WO2024133222A1 (en) | 2022-12-19 | 2024-06-27 | Belgian Volition Srl | Assessment of biological samples for nucleic acid analysis |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2652901A1 (fr) | 1989-10-11 | 1991-04-12 | Pasteur Institut | Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led). |
US6630301B1 (en) * | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
PT938320E (pt) * | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
ES2265682T3 (es) * | 1998-03-18 | 2007-02-16 | Roche Diagnostics Gmbh | Deteccion de productos apoptoticos. |
NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
EP1644519B1 (en) | 2003-07-04 | 2008-12-31 | Johnson & Johnson Research Pty Limited | Method for detection of alkylated cytosine in dna |
GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
CA2591717A1 (en) * | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
DE102005034628B4 (de) * | 2005-07-19 | 2007-08-23 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA |
WO2007050706A2 (en) | 2005-10-27 | 2007-05-03 | University Of Missouri-Columbia | Dna methylation biomarkers in lymphoid and hematopoietic malignancies |
WO2007049286A1 (en) * | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
AU2006330807A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of HMBG1 and/or rage and methods of use thereof |
DE102006035600B3 (de) | 2006-07-27 | 2007-11-08 | Epigenomics Ag | Verfahren zum Nachweis eines Methylierungsmusters |
US20080131954A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
EP2147124A4 (en) * | 2007-04-11 | 2010-07-14 | Manuel Esteller | EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER |
US7608402B2 (en) * | 2008-01-10 | 2009-10-27 | Weiwei Li | DNA methylation specific signal amplification |
WO2009115313A1 (en) | 2008-03-19 | 2009-09-24 | Oryzon Genomics, S.A. | Method and composition for methylation analysis |
EP3552622A3 (en) | 2008-11-21 | 2019-12-04 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
CN102460173A (zh) | 2009-04-14 | 2012-05-16 | 加利福尼亚大学董事会 | 组蛋白修饰用于癌症的临床诊断和预后 |
CN102612652B (zh) | 2009-08-06 | 2016-05-04 | 康奈尔大学 | 用于分子分析的设备和方法 |
US20130183662A1 (en) | 2010-04-22 | 2013-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
US20130078642A1 (en) | 2010-06-03 | 2013-03-28 | Porto Conte Richerche S.R.L. | Biomarkers for lung neuroendocrine tumors |
FI20105715A0 (fi) | 2010-06-18 | 2010-06-18 | Helsingin Yliopisto | Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine |
CN101955998A (zh) * | 2010-07-20 | 2011-01-26 | 赵英仁 | 一种血浆游离dna水平检测肝细胞坏死程度的方法 |
GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
PT2788767T (pt) * | 2011-12-07 | 2017-12-06 | Belgian Volition Sprl | Método de detecção de adutos de nucleosoma |
EP4155401A1 (en) | 2012-03-02 | 2023-03-29 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
GB201303575D0 (en) | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
-
2011
- 2011-09-01 GB GBGB1115095.0A patent/GB201115095D0/en not_active Ceased
-
2012
- 2012-08-31 PL PL12756549T patent/PL2751568T3/pl unknown
- 2012-08-31 CN CN201280053555.1A patent/CN104067124B/zh active Active
- 2012-08-31 AU AU2012300641A patent/AU2012300641B2/en active Active
- 2012-08-31 DK DK12756549.7T patent/DK2751568T3/en active
- 2012-08-31 RU RU2014112350/15A patent/RU2014112350A/ru unknown
- 2012-08-31 BR BR112014005087-2A patent/BR112014005087B1/pt not_active IP Right Cessation
- 2012-08-31 SG SG11201400270PA patent/SG11201400270PA/en unknown
- 2012-08-31 WO PCT/GB2012/052128 patent/WO2013030577A1/en active Application Filing
- 2012-08-31 MX MX2014002443A patent/MX364410B/es active IP Right Grant
- 2012-08-31 ES ES12756549T patent/ES2717659T3/es active Active
- 2012-08-31 CA CA2845993A patent/CA2845993C/en active Active
- 2012-08-31 RU RU2017126701A patent/RU2687483C2/ru active
- 2012-08-31 HU HUE12756549A patent/HUE043386T2/hu unknown
- 2012-08-31 US US14/239,783 patent/US10900064B2/en active Active
- 2012-08-31 JP JP2014527737A patent/JP6322845B2/ja active Active
- 2012-08-31 SG SG10201601153RA patent/SG10201601153RA/en unknown
- 2012-08-31 PT PT12756549T patent/PT2751568T/pt unknown
- 2012-08-31 KR KR1020147008108A patent/KR102074528B1/ko active IP Right Grant
- 2012-08-31 EP EP12756549.7A patent/EP2751568B1/en active Active
- 2012-08-31 TR TR2019/04386T patent/TR201904386T4/tr unknown
- 2012-08-31 EP EP18212025.3A patent/EP3483608B1/en active Active
-
2014
- 2014-02-20 ZA ZA2014/01295A patent/ZA201401295B/en unknown
-
2015
- 2015-01-08 HK HK15100175.0A patent/HK1199760A1/xx not_active IP Right Cessation
-
2019
- 2019-03-19 HR HRP20190533TT patent/HRP20190533T1/hr unknown
-
2020
- 2020-05-15 US US16/875,856 patent/US20200347435A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017126701A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
RU2018101257A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
JP2017215338A5 (ru) | ||
JP2014529405A5 (ru) | ||
JP2016500110A5 (ru) | ||
JP2014531573A5 (ru) | ||
EP3708682A3 (en) | Use of microvesicles in diagnosis and prognosis of medical diseases and conditions | |
WO2009132058A3 (en) | Levels of bcma protein expression on b cells and use in diagnostic methods | |
JP2008514209A5 (ru) | ||
RU2008123406A (ru) | Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента | |
EA200800963A1 (ru) | Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты | |
WO2009092386A8 (en) | A new method to measure and characterize microvesicles in the human body fluids | |
WO2006091412A3 (en) | Adamts-7 as a biomarker for cancers of epithelial origin | |
DE602006019262D1 (de) | QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN | |
JP2018536849A5 (ru) | ||
FI2398902T3 (fi) | Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten | |
BR112014013544A2 (pt) | materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata | |
RU2010101909A (ru) | Способ выявления или лечения реакции "трансплантат против хозяина" | |
Clarke et al. | Quantification of tissue shrinkage in canine small intestinal specimens after resection and fixation | |
RU2016104892A (ru) | Композиции и способы для идентификации риска развития ракового заболевания у субъекта | |
JP2018529931A5 (ru) | ||
JP2012520446A5 (ru) | ||
US8278053B2 (en) | Methods of studying a biomarker, and methods of detecting a biomarker | |
RU2012151434A (ru) | Комбинированная терапия и способ оценки невосприимчивости к лечению | |
WO2006044566A3 (en) | Autocrine growth factor receptors and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant |